S.Korea's ST Pharm supplies $49 mn worth of APIs to European drug firm

This contract accounts for 38% of the company's consolidated sales revenue in 2021

S.Korea's ST Pharm supplies  mn worth of APIs to European drug firm
Jeong Min Nam 1
2023-03-24 10:13:28 peux@hankyung.com
Bio & Pharma

ST Pharm Co., a South Korean pharmaceutical firm, announced on Thursday that it had entered into an agreement to supply oligonucleotides to an undisclosed European multinational pharmaceutical company.

These oligonucleotides serve as the raw materials for developing therapeutic drugs that employ antisense oligonucleotide technology, which operates at the gene level.

The contract is valued at 63.1 billion won ($49.1 million), representing roughly 38% of the company's consolidated sales revenue for 2021.

Antisense oligonucleotide technology relies on substances like RNA and DNA to create therapeutic drugs that target genetic material.

ST Pharm operates as a raw material pharmaceutical subsidiary of Dong-A Socio Holdings and handles the consignment production of antisense oligonucleotide treatments.

Write to Jeong Min Nam at peux@hankyung.com

Korea's ST Pharm completes new R&D hub for gene therapy

Korea's ST Pharm completes new R&D hub for gene therapy

ST Pharm Co., a South Korean drug raw material-producing subsidiary of Dong-A Socio Holdings, said on Friday that it has finished building an R&D Innovation Center in Ansan City, Gyeonggi Province.The 12-story center, which spans 5,166 square meters and cost 18 billion won ($14 million) to

ST Pharm exports $14.6 mn worth of drug ingredients to Europe

ST Pharm exports $14.6 mn worth of drug ingredients to Europe

ST Pharm Co., a South Korean company specializing in contract development and manufacturing of drug ingredients, has signed a supply contract worth 18 billion won ($14.6 million) with a large European pharmaceutical company.With the company regaining sales of 200 billion won first in five year

(* comment hide *}